Idera Pharmaceuticals (NASDAQ:IDRA) announced on June 5th that it had initiated enrollment in a Phase 2 trial of IMO-8400, one of its lead drug candidates, for patients with mild to severe plaque psoriasis. The announcement was a bit more significant than many investors were aware of apparently, as there was little share price or volume response with only 127,250 shares changing hands that day. Buried in the announcement was the phrase announcing "Data from the Phase 1 study will be presented at a scientific meeting in June 2013." The data was indeed presented in June and subsequently announced on July 1st via a corporate press release. The data were promising in the single...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|